Get Updates on MIGS

DON'T WAIT

FOR TOO LATE

Glaucoma is a silent threat that can lurk

below the surface. Minimally invasive

glaucoma surgery (MIGS), performed as

a solo procedure or with cataract

surgery, may be the best option for

your glaucoma patients.

DON'T WAIT

FOR TOO LATE

Glaucoma is a silent threat that can lurk below the surface. Minimally invasive glaucoma surgery (MIGS), performed as a solo procedure or with cataract surgery, may be the best option for your glaucoma patients.

lifevest

WHAT YOU KNOW

ABOUT IOP IS TRUE

IOP Reduction Is the Only Way to Manage Glaucoma

Early Intervention Is Essential to Slowing Progression of the Disease​

WHAT YOU KNOW

ABOUT IOP IS TRUE

IOP Reduction Is the Only Way to Manage Glaucoma

Early Intervention Is Essential to Slowing Progression of the Disease​

THE TREATMENT BURDEN YOU SEE DAILY IS REAL

Drop Therapy Can Create Challenges for Glaucoma Patients

THE TREATMENT BURDEN YOU SEE DAILY IS REAL

Drop Therapy Can Create Challenges for Glaucoma Patients

compass

THERE'S A SOLUTION IN SIGHT

MIGS Allows You to Proactively Treat Glaucoma

When considered early, the benefits of MIGS spans the spectrum.

CONSIDER MIGS EARLY

THERE'S A SOLUTION IN SIGHT

CONSIDER MIGS EARLY

When considered early, the benefits of MIGS spans the spectrum.

DON'T WAIT FOR

TOO LATE

Fill out the form to find out what MIGS can do for your patients.

References:

1. The Advanced Glaucoma Intervention Study (AGIS): 7. The Relationship Between Control of Intraocular Pressure and Visual Field Deterioration. American Journal of Ophthalmology, vol. 30, no. 4, Oct. 2020, pp. 429–437.
2. Robin, Alan, and Davinder S Grover. Compliance and Adherence in Glaucoma Management.” Indian Journal of Ophthalmology, vol. 59, no. 7, Jan. 2011, pp. 93–96., doi:10.4103/0301-4738.73693.
3. MacKean, J M, and A R Elkington. Compliance with Treatment of Patients with Chronic Open-Angle Glaucoma. British Journal of Ophthalmology, vol. 67, 1983, pp. 46–49.
4. Kim, Chan Yun, et al. Treatment Patterns and Medication Adherence of Patients with Glaucoma in South Korea.” British Journal of Ophthalmology, vol. 101, no. 6, 2017, pp. 801–807., doi:10.1136/bjophthalmol-2016-308505.
5. Gazzard, Gus, et al. Selective Laser Trabeculoplasty versus Eye Drops for First-Line Treatment of Ocular Hypertension and Glaucoma (LiGHT): a Multicentre Randomised Controlled Trial. The Lancet, vol. 393, no. 10180, 2019, pp. 1505–1516., doi:10.1016/s0140-6736(18)32213-x.
6. Inoue, Kenji. “Managing Adverse Effects of Glaucoma Medications.” Clinical Ophthalmology, 2014, p. 3., doi:10.2147/opth.s44708.
7. “2019 Glaucoma Surgical Device Market Report .” Market Scope, Aug. 2019, p. 127.

© 2021 Sight Sciences, Inc. 12/21 OM-1916-US.v2

|

DON'T WAIT FOR TOO LATE

Fill out the form to find out what MIGS can do for your patients.

References:

1. The Advanced Glaucoma Intervention Study (AGIS): 7. The Relationship Between Control of Intraocular Pressure and Visual Field Deterioration. American Journal of Ophthalmology, vol. 30, no. 4, Oct. 2020, pp. 429–437.
2. Robin, Alan, and Davinder S Grover. Compliance and Adherence in Glaucoma Management.” Indian Journal of Ophthalmology, vol. 59, no. 7, Jan. 2011, pp. 93–96., doi:10.4103/0301-4738.73693.
3. MacKean, J M, and A R Elkington. Compliance with Treatment of Patients with Chronic Open-Angle Glaucoma. British Journal of Ophthalmology, vol. 67, 1983, pp. 46–49.
4. Kim, Chan Yun, et al. Treatment Patterns and Medication Adherence of Patients with Glaucoma in South Korea.” British Journal of Ophthalmology, vol. 101, no. 6, 2017, pp. 801–807., doi:10.1136/bjophthalmol-2016-308505.
5. Gazzard, Gus, et al. Selective Laser Trabeculoplasty versus Eye Drops for First-Line Treatment of Ocular Hypertension and Glaucoma (LiGHT): a Multicentre Randomised Controlled Trial. The Lancet, vol. 393, no. 10180, 2019, pp. 1505–1516., doi:10.1016/s0140-6736(18)32213-x.
6. Inoue, Kenji. “Managing Adverse Effects of Glaucoma Medications.” Clinical Ophthalmology, 2014, p. 3., doi:10.2147/opth.s44708.
7. “2019 Glaucoma Surgical Device Market Report .” Market Scope, Aug. 2019, p. 127.

© 2021 Sight Sciences, Inc. 10/21 OM-1916-US.v1

|